PMID- 32458838
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2047-4849 (Electronic)
IS  - 2047-4830 (Linking)
VI  - 8
IP  - 13
DP  - 2020 Jul 7
TI  - Biomimetic oral targeted delivery of bindarit for immunotherapy of 
      atherosclerosis.
PG  - 3640-3648
LID - 10.1039/d0bm00418a [doi]
AB  - Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the 
      development of atherosclerosis. However, the application of bindarit (a specific 
      synthetic inhibitor of MCP-1) in atherosclerosis has not been confirmed due to 
      the non-specific distribution profile in vivo. Herein, based on the recruitment 
      of monocytes into atherosclerotic plaques, we successfully delivered bindarit 
      into the interior of atherosclerotic plaques through a yeast-derived microcapsule 
      (YC) mediated biomimetic approach. In this biomimetic approach, bindarit was 
      firstly assembled with polyethyleneimine to form the positively charged 
      nanoparticles (BIN/PEI NPs) via multiple intermolecular forces, and then the 
      obtained BIN/PEI NPs were packed into YCs by electrostatic force-mediated 
      spontaneous deposition. Through an oral adsorption routine similar to yeasts, 
      bindarit loaded YCs (BIN/YCs) were distributed into peripheral blood monocytes 
      after oral administration, and then their targeted delivery to atherosclerotic 
      plaques was successfully performed through monocyte transportation. 
      Correspondingly, oral delivery of bindarit loaded YCs afforded notably 
      potentiated efficacies for inhibiting the MCP-1 and further reducing the 
      recruitment of monocytes into atherosclerotic plaques, and thus presented a good 
      efficacy in preventing the formation of atherosclerotic plaques. These results 
      demonstrated that a 'Trojan horse'-like YC mediated nanomedicine delivery 
      strategy is expected to realize the application of certain potential 
      anti-inflammatory drugs in the treatment of atherosclerosis and is of great 
      significance for the development of novel strategies for atherosclerosis 
      treatment.
FAU - Yin, Luqi
AU  - Yin L
AD  - Department of Pharmaceutics, College of Pharmacy, Third Military Medical 
      University, Chongqing 400038, China. diszhou@126.com diszhou@cqut.edu.cn 
      lpsh008@aliyun.com.
FAU - Peng, Cuiping
AU  - Peng C
FAU - Tang, Yue
AU  - Tang Y
FAU - Yuan, Yuchuan
AU  - Yuan Y
FAU - Liu, Jiaxing
AU  - Liu J
FAU - Xiang, Tingting
AU  - Xiang T
FAU - Liu, Feila
AU  - Liu F
FAU - Zhou, Xing
AU  - Zhou X
FAU - Li, Xiaohui
AU  - Li X
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - Biomater Sci
JT  - Biomaterials science
JID - 101593571
RN  - 0 (Biocompatible Materials)
RN  - 0 (CY5.5 cyanine dye)
RN  - 0 (Carbocyanines)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Indazoles)
RN  - 0 (Propionates)
RN  - JQ11LH711M (bindarit)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Biocompatible Materials/administration & dosage/*chemistry/pharmacology
MH  - *Biomimetics
MH  - Carbocyanines/administration & dosage/chemistry
MH  - Cells, Cultured
MH  - Chemokine CCL2/antagonists & inhibitors
MH  - Dose-Response Relationship, Drug
MH  - *Drug Delivery Systems
MH  - *Immunotherapy
MH  - Indazoles/administration & dosage/*chemistry/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Plaque, Atherosclerotic/immunology/*therapy
MH  - Propionates/administration & dosage/*chemistry/pharmacology
MH  - RAW 264.7 Cells
EDAT- 2020/05/28 06:00
MHDA- 2021/03/11 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1039/d0bm00418a [doi]
PST - ppublish
SO  - Biomater Sci. 2020 Jul 7;8(13):3640-3648. doi: 10.1039/d0bm00418a. Epub 2020 May 
      27.